Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate.
about
Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residuesVEGF-Trap: a VEGF blocker with potent antitumor effects.Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alphaSemaphorin-PlexinD1 signaling limits angiogenic potential via the VEGF decoy receptor sFlt1Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activityPathways for aberrant angiogenesis in pancreatic cancerMatrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165Suppression of tumor growth by palm tocotrienols via the attenuation of angiogenesisEffect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growthSelection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy.Arginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis.Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy.A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor.Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors.Emerging biological therapies for age-related macula degeneration.Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.VEGF promotes malaria-associated acute lung injury in miceAngiogenesis in urological malignancy: prognostic indicator and therapeutic target.Maternal and fetoplacental hypoxia do not alter circulating angiogenic growth effectors during human pregnancy.Targeting avian leukosis virus subgroup A vectors by using a TVA-VEGF bridge protein.Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivoCurrent status of antiangiogenic factors.Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors.The role of angiogenesis in rheumatoid arthritis: recent developmentsCancer gene therapy: developments to 2000.Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis.Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in miceVEGF antagonists.PEI-g-PEG-RGD/small interference RNA polyplex-mediated silencing of vascular endothelial growth factor receptor and its potential as an anti-angiogenic tumor therapeutic strategyAntiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development.An increase in vascular endothelial growth factor (VEGF) and VEGF soluble receptor-1 (sFlt-1) are associated with early recurrent spontaneous abortion.Rapid vascular regrowth in tumors after reversal of VEGF inhibition.Molecular pathogenesis and prognostic factors in endometrial carcinoma.Cancer gene therapy.Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.Increased production of soluble vascular endothelial growth factors receptor-1 in CHO-cell line by using new combination of chitosan-protein lipid nanoparticlesGene therapy of hepatocarcinoma: a long way from the concept to the therapeutical impact.Perlecan and tumor angiogenesis.Plasma vascular endothelial growth factor, soluble VEGF receptor FLT-1, and von Willebrand factor in glaucoma.Parvovirus vectors for cancer gene therapy.
P2860
Q22008806-E1305E81-70D8-4098-BB4B-2573F111C2CEQ24535043-717B8DC8-99D1-49BE-A6EE-453532D41483Q24610199-23F77C4F-662F-41BA-AF35-49989BAB7134Q24617241-E102ACAE-B3B0-4D16-AC05-B43C0217EDC2Q24677555-789E29D7-19E3-4918-84CC-F291BF697E8BQ24800215-E8758693-4468-49F6-AC02-D3A69FD12056Q28214421-601C094C-08ED-4D93-A318-C0F54889BE9DQ28241644-FA1F7EFD-532C-47E7-8559-F44256E0C6B5Q28366604-31FB163A-D327-496D-B78C-9DB305F2DC91Q30790872-04C61E4D-FE62-40BD-9044-C280FFAEA303Q30864689-9F63476C-A158-4DCD-9231-F54BA16CE879Q31065469-152F3489-C07D-4185-A27D-3E6DCE2354DFQ31104595-21FB3CEA-B12A-4171-89FD-316E9EED7185Q31155271-BFF9E35C-1445-460F-A79E-BA5FE6F2FDD4Q33224360-472A2AAB-A125-4956-9DF0-D494C4143D18Q33558337-B69AADD9-47DC-405A-A4BF-410C5F9F9259Q33587506-0BA03A21-CC2E-4876-9164-2443615E1521Q33598141-99C7E104-FD55-4245-A1FE-636CB900EDC6Q33826353-AF7AB9A1-D3A8-47E8-873D-33C50C2C365DQ33837118-6AACF6C5-D897-467E-B216-828797BDC477Q33852232-44B0E72B-28CA-49FF-988B-81DE19ACAD7EQ33962049-95CE2201-3403-4F2E-85A3-045262DA7229Q34068188-502005F2-7625-4BD3-A3E8-285539149740Q34071300-5117AA8C-A296-4112-823D-6578929C18E3Q34090963-B41830A4-C7F1-4EAE-9FCA-D0944D0887B5Q34130552-E25894D2-F645-4596-A8F8-C2717A8A299AQ34245416-DCC321C6-E5F0-4D99-9C13-2A96BF405638Q34451927-8F73EB0A-9952-4329-8E7F-8FD5A4029957Q34805909-DB105DD9-F681-4961-820D-2140AAD05D44Q34974876-D55AADA8-E1F4-4774-8064-BCF7A172E63BQ35010082-5528C16D-4B10-439F-9E25-CCA6FDB2C5F9Q35052385-D59EFFD3-DA5C-4878-9C4B-CA7D9FABC558Q35065032-024757CF-D27A-480D-B1F0-8BAC95BF521AQ35081097-D7820FBE-E295-4F0D-AD22-22744DB1948BQ35102889-5DFA57B2-2BD2-4709-9E19-8B921D74D89EQ35174005-3A198424-0B2A-4AA8-8396-8B35117CFE71Q35208038-A7E808C0-2328-4BE8-893E-3FA881840E90Q35562693-F2570DCE-D5D6-4732-B027-F50F5D89D7C2Q35590232-3F4ECEE1-DCBE-4649-AF6C-E65E9D08C541Q35609780-10DBD453-A76F-48DF-B576-B6D36148C141
P2860
Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Paracrine expression of a nati ...... etastasis, and mortality rate.
@ast
Paracrine expression of a nati ...... etastasis, and mortality rate.
@en
type
label
Paracrine expression of a nati ...... etastasis, and mortality rate.
@ast
Paracrine expression of a nati ...... etastasis, and mortality rate.
@en
prefLabel
Paracrine expression of a nati ...... etastasis, and mortality rate.
@ast
Paracrine expression of a nati ...... etastasis, and mortality rate.
@en
P2093
P2860
P356
P1476
Paracrine expression of a nati ...... etastasis, and mortality rate.
@en
P2093
C K Goldman
G P Siegal
G Y Gillespie
K A Thomas
L Soroceanu
R L Kendall
W R Huckle
P2860
P304
P356
10.1073/PNAS.95.15.8795
P407
P577
1998-07-01T00:00:00Z